Friday, March 05, 2010 3:39:36 PM
Why no follow-up results? IMHO
Just my two cents, but I think a couple of things contribute to the slow follow-up.
First, I think that once the "cide" is initially tested and shows good results, the tester and the company start to assess how to make it better. The process to create a "cide" which is slight different is not as simple as we novices hope. i also think that creating one kind of "cide" then stopping that process and beginning to create another "cide" has been difficult without the manufacturing facility. I think the lab environment is just a slow process when trying to create enough product for the tester to use, particularly given that there are about 8 different ones.
I also think that the toxicity testing takes longer than we would like because the protocols demand the passage of time to assess what happens to the animal over time. Take for example the EKC-cide, it might take care of the EKC but the protocol demands the bunny not go blind 6 months later. But you won't know that for six months. JMHO (I am long and have drank the koolaid, full disclosure.)
Just my two cents, but I think a couple of things contribute to the slow follow-up.
First, I think that once the "cide" is initially tested and shows good results, the tester and the company start to assess how to make it better. The process to create a "cide" which is slight different is not as simple as we novices hope. i also think that creating one kind of "cide" then stopping that process and beginning to create another "cide" has been difficult without the manufacturing facility. I think the lab environment is just a slow process when trying to create enough product for the tester to use, particularly given that there are about 8 different ones.
I also think that the toxicity testing takes longer than we would like because the protocols demand the passage of time to assess what happens to the animal over time. Take for example the EKC-cide, it might take care of the EKC but the protocol demands the bunny not go blind 6 months later. But you won't know that for six months. JMHO (I am long and have drank the koolaid, full disclosure.)
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
